Investing.com - TG (NASDAQ: TGTX) reported first quarter EPS of $-0.28, $0.08 better than the analyst estimate of $-0.36. Revenue for the quarter came in at $7.8M versus the...
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), for...
First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+ healthcare providers at 125+ centers Payor coverage in...
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, May 1, 2023, at 8:30 ET to discuss...
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
|Average||29.81 (+9.60% Upside)|
|No. of Analysts||8|
|Technical Indicators||Buy||Strong Buy||Neutral||Strong Sell||Strong Buy|
Invista REIM Holdingsderived